ZURICH, Switzerland, Oct. 15, 2007 (PRIME NEWSWIRE) -- Nobel Biocare (Other OTC:NBCHF) today announced that with effect of 1 December 2007 Petra Rumpf (40) is appointed to the Executive Committee as Head of Business Development and Strategic Planning. She joins Nobel Biocare from CapGemini where she is Vice President and member of the Central European management team. As former head of the strategy unit in Central Europe and global head of M&A, Petra has gained extensive experience in strategy development, change management and M&A. Together with her team she recently won the 2007 ASCO (Swiss association of management consultants) award for the "Best Business Transformation". Petra Rumpf is a German citizen and holds a degree in economics and an MBA from Clark University, Massachusetts (USA).
Domenico Scala, CEO said: "I'm particularly pleased that with Petra Rumpf we have been able to appoint a highly experienced professional in the area of business development. My colleagues and I look forward to working with her as we continue to develop Nobel Biocare as the leading provider of innovative dental solutions."
For more information about Nobel Biocare visit www.nobelbiocare.com
Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands Branemark System(r), NobelReplace(tm), NobelSpeedy(tm), NobelPerfect(r), NobelDirect(r), Replace Select, (dental implants), Procera(r) (individualized dental prosthetics), NobelGuide(tm) (complete patient rehabilitation program) and NobelSmile(tm) (patient education website). Nobel Biocare is a one-stop shop for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,100 employees and recorded revenue of EUR 601 million in 2006. The Company is domiciled in Zurich, Switzerland with headquarters in Zurich and in Gothenburg, Sweden. Production takes place at five production sites located in Sweden and the USA. Nobel Biocare has direct sales organizations in 34 countries. The shares of the parent company Nobel Biocare Holding AG are listed on SWX Swiss Exchange and OMX Stockholm, Sweden. www.nobelbiocare.com